AC Immune (NASDAQ:ACIU – Get Free Report) is set to announce its earnings results on Friday, April 26th.
AC Immune (NASDAQ:ACIU – Get Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $16.71 million for the quarter, compared to the consensus estimate of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AC Immune Trading Down 0.4 %
Shares of NASDAQ:ACIU opened at $2.37 on Thursday. The stock’s 50-day moving average price is $3.12 and its 200-day moving average price is $3.34. AC Immune has a 12-month low of $1.78 and a 12-month high of $5.14. The stock has a market capitalization of $234.39 million, a P/E ratio of -3.34 and a beta of 1.00.
Analyst Ratings Changes
Read Our Latest Analysis on ACIU
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also
- Five stocks we like better than AC Immune
- Options Trading – Understanding Strike Price
- High-Yield Texas Instruments Could Hit New Highs Soon
- Investing in Construction Stocks
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Tickers Leading a Meme Stock Revival
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.